Skip to main content

Table 1 (abstract P18). Relapse rate in non-systemic JIA patients after withdrawal of bDMARD

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

Main author (n)

Chang (25*, 7#)

Aquilani (110)

Anink (26)

Lovell (106)

Leong (39)

Iglesias (18)

Windschall (24)

Hissink Muller (19)

Foeldvari (22)

Medication type

Etanercept Adalimumab Infliximab

Etanercept

Etanercept

Etanercept Adalimumab Infliximab

Etanercept Adalimumab Infliximab

Etanercept Adalimumab Infliximab

Etanercept

Etanercept

Etanercept

Time in inactive disease, months, mean (range)

unknown

14.6

at least 6

at least 6

al least 6

12.2

at least 18

5.8 (3-6)

unknown

Follow up duration, months

unknown

12

6

8

8

unknown

unknown

unknown

unknown

% relapse after withdrawal

78%, 76%

60%

46.2%

36.8%

46.2%

77.8%

50%

26.3%

59.1%

Time to relapse, months, mean (range) and/or [median (range)]

unknown

[4.3]

unknown

7, [8.3]

unknown

3

8.4 (4-72)

[3 (3-6.8)]

[7]

% relapse after 6 months

47%, 48%

40%

46.2%

      

% relapse after 8 months

   

36.8%

46.2%

    

% relapse after 12 months

78%, 76%

60%

       
  1. *bDMARD with concomitant methotrexate, #bDMARD monotherapy